Analytical Data
-
Gene name
IL31RA
-
简介
The IL-31R alpha protein is critical to the immune response and forms the interleukin 31 receptor with OSMR. It activates STAT3, and to a lesser extent STAT1 and STAT5, is associated with skin immunity and mediates IL31-induced itch, possibly involving the cation channels TRPA1 and TRPV1. IL-31R alpha Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived IL-31R alpha protein, expressed by HEK293, with C-hFc labeled tag.
- Application
-
Alternative Names
IL-31RA; IL-31R-alpha; Gp130-like receptor; CRL3; GPL; ZcytoR17; GLM-R; CRL3Glmr; GLM-RMGC125346; PRO21384
-
Species
Mouse
-
Source
HEK293
-
Tag
C-hFc
-
Purity
> 90% as determined by SDS-PAGE.
-
Uniprot
Q8K5B1
-
Expression Region
V19-T499
-
Molecular Weight
110-130 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-31RA (Interleukin-31 Receptor A) is a crucial component of the IL-31 signaling pathway, which is implicated in various inflammatory and allergic conditions, particularly in skin diseases such as atopic dermatitis. IL-31, a cytokine produced predominantly by Th2 cells, binds to IL-31RA, initiating a cascade of signaling events that contribute to pruritus (itching), inflammation, and other pathological responses. The receptor's expression is notably observed in epithelial cells, immune cells, and neurons, highlighting its role in mediating the effects of IL-31 in different tissues. Due to its involvement in inflammatory diseases, IL-31RA has emerged as a potential therapeutic target for interventions aimed at alleviating itching and inflammation. Research on recombinant IL-31RA proteins focuses on understanding their structure, function, and interaction with IL-31, enabling the development of targeted therapies that can block this pathway. Additionally, the exploration of IL-31RA as a biomarker for disease severity in atopic conditions could provide further insights into personalized treatment approaches. Overall, the study of IL-31RA recombinant proteins holds promise for advancing our understanding of immune-mediated diseases and improving clinical outcomes for patients suffering from chronic inflammatory conditions.
